BioNTech is no longer a buy, says analyst

A Bryan Garnier prognosticator increases her price target despite the recommendation chop.

| More on:
vaccine

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade.

In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.

BioNTech shot to fame last year due to that vaccine, BNT162b2, which it co-developed with pharmaceutical giant Pfizer. Both became popular coronavirus stocks, particularly after the jab was authorized for emergency use in both the the U.S. and the European Union -- two massive markets -- in December.

This pushed BioNTech's results high into the sky; last Friday, the company unveiled its first-quarter results, showing higher-than-expected revenue growth of nearly 7,300% and a flip deep into the black on the bottom line.

BNT162b2 should find its way into more American arms; on Monday, the FDA expanded its Emergency Use Authorization for the vaccine to include adolescents ages 12 to 15. The regulator quoted its acting commissioner, Janet Woodcock, as saying that this "allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic."

But many investors might consider BioNTech's explosive growth story to be over. In terms of both cases and fatalities, the pandemic is receding across the U.S., plus the Biden administration has indicated its support for patent waivers on coronavirus vaccines.

At any rate, Smolentseva's new outlook on the stock isn't doing it any favors. In late afternoon trading Tuesday, BioNTech was down by 2.2% while the S&P 500 index was falling 1.9%.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on International Stock News

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
International Stock News

The CEO of Nvidia just sold 700,000 shares of his company's stock. Here's what investors need to know

What could it mean?

Read more »

A man in a business suit peers through binoculars as two businesswomen stand beside him looking straight ahead at the camera.
International Stock News

Where will Nvidia stock be in 1 year?

You might be late to the party.

Read more »

asx share price boosted by us investment represented by hand waving US flag across winning athlete
International Stock News

Is it too late for ASX investors to start buying US shares?

Should ASX investors start taking the gains from US shares like Nvidia off the table?

Read more »

A US flag behind a graph, indicating investment in US shares
International Stock News

Which US shares are ASX investors buying in 2024?

The ASX's most popular US shares contain some familiar names...

Read more »

A man and a woman sit in front of a laptop looking fascinated and captivated.
International Stock News

Prediction: 2 US stocks that will be worth more than Nvidia 5 years from now

These US stocks have a shot at surpassing Nvidia over the next few years.

Read more »

Digital rocket on a laptop.
International Stock News

Is Nvidia stock going to $150 in the wake of its high-profile 10-for-1 stock split?

Wall Street analysts are reviewing their models in the wake of Nvidia's stock split.

Read more »

A woman walks along the street holding an oversized box wrapped as a gift.
International Stock News

Better megacap stock: Nvidia vs. Microsoft

Megacap stocks have ruled the year so far. Is Nvidia or Microsoft better positioned for the second half of the…

Read more »

A man casually dressed looks to the side in a pensive, thoughtful manner with one hand under his chin, holding a mobile phone in his hand while thinking about something.
International Stock News

Is Nvidia stock a buy now?

Nvidia investors are looking ahead. But there is risk in counting on things that haven't happened yet.

Read more »